Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB)

Arch Biopartners Inc (ARCH:TSXV) (ACHFF:OTCQB)

Arch Biopartners Inc is a late stage clinical trial company focused on the development of novel therapeutics targeting organ inflammation. The company, founded in 2010 and headquartered in Canada, collaborates closely with the scientific community, universities, and research institutions to advance and build the value of select medical innovations. With a strong patent portfolio of new drug candidates to prevent inflammation and organ injury, Arch has made significant strides in its clinical trials.

The company's Phase I and Phase II clinical trials resulted in the LSALT peptide (Metablok) becoming the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada. Moreover, Arch's scientists have described a novel mechanism of action for organ inflammation, identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil adhesion receptor in the lungs, kidneys, and liver, and demonstrated that DPEP1 is the target of LSALT peptide (Metablok), the company’s lead drug candidate targeting inflammation in the lungs and kidneys.

Currently, Arch is working to advance LSALT peptide through the production of additional human safety and efficacy data in a Phase II trial to prevent IRI-acute kidney injury (AKI). The company recently received a $4.00M grant investment from the National Research Council of Canada Industrial Research Assistance Program on 23 March 2023. With these developments, investors and enthusiasts are encouraged to follow Arch on LinkedIn and subscribe to its website for the latest science and investor news.